The HEMO share price tracks Hemogenyx Pharmaceuticals Plc, a clinical-stage biopharma developing treatments for blood and autoimmune disease. Here’s the current price, its 52-week range, and what actually drives it.
Price and market data below were last checked on 24 August 2026. Share prices change throughout each trading day, so always verify against a live quote before making any decision.
Quick Answer: HEMO Share Price
The HEMO share price sits at 667.00 pence, up 4.22% on the day, giving Hemogenyx Pharmaceuticals a market cap near £45.36 million. It trades on London’s AIM market under ticker HEMO, with roughly 6.80 million shares in issue. Because this is a snapshot rather than a live feed, check a real-time quote before trading — nothing here is financial advice.
1. HEMO Share Price Today
- Price: 667.00 pence, up about 4.22% on the day.
- Market: London Stock Exchange, AIM market, ticker HEMO.
- Market cap: Roughly £45.36 million, based on a small share count of about 6.80 million shares.
- Why the price looks high: So a small share count with a modest market cap can still show a price in the hundreds of pence, unlike most AIM stocks priced in single pence.
2. HEMO 52-Week Range and Volatility
- 52-week high: 1,790.00 pence, reached in September 2025.
- 52-week low: 133.50 pence, reached in August 2025.
- What that swing means: So the stock has moved more than tenfold across the past year, extreme even for a clinical-stage biotech.
- Why it swings so much: Because Hemogenyx has no product revenue yet, trial results and regulatory news each tend to trigger outsized single-day moves.
3. What Hemogenyx Pharmaceuticals Does
- Core business: Hemogenyx develops new treatments for blood and autoimmune diseases, working across several clinical-stage drug programmes.
- Why that matters: So a successful trial result or regulatory approval can transform the company’s value almost overnight.
- Stage: The company is pre-revenue and clinical-stage, so its share price leans entirely on trial progress rather than earnings.
- Funding: Like most clinical-stage biotechs, Hemogenyx relies on periodic share placings to fund its trials, which can dilute existing shareholders.
4. Key Factors That Move the HEMO Share Price
- Clinical trial results: Positive or negative trial data is the single biggest trigger for a sharp price move.
- Regulatory news: Updates from health regulators on trial approvals or holds can swing the stock heavily in either direction.
- Funding rounds: A fresh placing can pressure the price short term, even when the underlying trial news is positive.
- Biotech sector sentiment: Small-cap biotech stocks often move together during broader risk-appetite shifts across the sector.
Before You Trade HEMO Shares
- Check a live quote first. Clinical-stage biotech stocks can move fast around trial news.
- Read the RNS feed. Company announcements on the London Stock Exchange site carry the facts behind any price move.
- Understand the risk. Because pre-revenue biotechs carry high clinical and regulatory risk, this article is informational, not investment advice.
- Watch dilution. Track the share count over time, since future fundraising can affect existing shareholders.
For related reading, see our guides to UKOG Share Price: UK Oil & Gas Stock Today (2026) and THG Share Price: THG plc Stock Today (2026).
FAQ: HEMO Share Price
What is the HEMO share price today?
Around 667.00 pence, up roughly 4.22% on the day, with a market cap near £45.36 million.
What does Hemogenyx Pharmaceuticals do?
It develops clinical-stage treatments for blood and autoimmune diseases.
Why is the HEMO share price so volatile?
As a pre-revenue biotech, its price reacts sharply to clinical trial results, regulatory news, and funding updates.
Is HEMO on the FTSE?
No. HEMO trades on London’s AIM market, a segment built for smaller and growth-stage companies.
Where can I check the live HEMO share price?
The London Stock Exchange site and major finance data providers publish live AIM quotes through the trading day.
You may also like
[…] might also find our HEMO Share Price: Hemogenyx Pharma Stock Today (2026) guide […]